Pullamsetti Soni S, Perros Frédéric, Chelladurai Prakash, Yuan Jason, Stenmark Kurt
Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, member of the German Center for Lung Research (DZL), Bad Nauheim, Germany; Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), member of the DZL, Justus-Liebig University, Giessen, Germany.
Université Paris-Sud; and Institut national de la santé et de la recherche médicale (Inserm) Unité Mixte de Recherche (UMR_S) 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
Pulm Circ. 2016 Dec;6(4):448-464. doi: 10.1086/688908.
Pulmonary hypertension (PH) is a complex and multifactorial disease involving genetic, epigenetic, and environmental factors. Numerous stimuli and pathological conditions facilitate severe vascular remodeling in PH by activation of a complex cascade of signaling pathways involving vascular cell proliferation, differentiation, and inflammation. Multiple signaling cascades modulate the activity of certain sequence-specific DNA-binding transcription factors (TFs) and coregulators that are critical for the transcriptional regulation of gene expression that facilitates PH-associated vascular cell phenotypes, as demonstrated by several studies summarized in this review. Past studies have largely focused on the role of the genetic component in the development of PH, while the presence of epigenetic alterations such as microRNAs, DNA methylation, histone levels, and histone deacetylases in PH is now also receiving increasing attention. Epigenetic regulation of chromatin structure is also recognized to influence gene expression in development or disease states. Therefore, a complete understanding of the mechanisms involved in altered gene expression in diseased cells is vital for the design of novel therapeutic strategies. Recent technological advances in DNA sequencing will provide a comprehensive improvement in our understanding of mechanisms involved in the development of PH. This review summarizes current concepts in TF and epigenetic control of cell phenotype in pulmonary vascular disease and discusses the current issues and possibilities in employing potential epigenetic or TF-based therapies for achieving complete reversal of PH.
肺动脉高压(PH)是一种复杂的多因素疾病,涉及遗传、表观遗传和环境因素。众多刺激因素和病理状况通过激活一系列复杂的信号通路,包括血管细胞增殖、分化和炎症,促使PH发生严重的血管重塑。多项信号级联反应调节某些序列特异性DNA结合转录因子(TFs)和共调节因子的活性,这些因子对于促进与PH相关的血管细胞表型的基因表达的转录调控至关重要,本综述中总结的多项研究已证实这一点。过去的研究主要集中在遗传成分在PH发生中的作用,而诸如微小RNA、DNA甲基化、组蛋白水平和组蛋白去乙酰化酶等表观遗传改变在PH中的存在如今也受到越来越多的关注。染色质结构的表观遗传调控也被认为会影响发育或疾病状态下的基因表达。因此,全面了解患病细胞中基因表达改变所涉及的机制对于设计新的治疗策略至关重要。DNA测序方面的最新技术进展将全面提升我们对PH发生机制的理解。本综述总结了肺血管疾病中细胞表型的TF和表观遗传调控的当前概念,并讨论了采用潜在的基于表观遗传或TF的疗法实现PH完全逆转的当前问题和可能性。